| Entry |
| ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Name | Idarubicin hydrochloride (JP18/USP); Idamycin (TN) | ||||||||||
| Product | IDAMYCIN PFS (Pfizer Laboratories Div Pfizer) | ||||||||||
| Generic | IDARUBICIN HYDROCHLORIDE (Hikma Pharmaceuticals USA), IDARUBICIN HYDROCHLORIDE (Hikma Pharmaceuticals USA), IDARUBICIN HYDROCHLORIDE (Teva Parenteral Medicines) | ||||||||||
| Formula | C26H27NO9. HCl | ||||||||||
| Exact mass | 533.1453 | ||||||||||
| Mol weight | 533.9548 | ||||||||||
| Structure |  | ||||||||||
| Simcomp | |||||||||||
| Class | Antineoplastic DG01682 Anthracycline antineoplastic DG01529 Topoisomerase inhibitor DG01527 Topoisomerase II inhibitor | ||||||||||
| Remark |
| ||||||||||
| Efficacy | Antineoplastic, Topoisomerase II inhibitor | ||||||||||
| Disease | Acute myeloid leukemia [DS:H00003] | ||||||||||
| Target | TOP2 [HSA:7153 7155] [KO:K03164] | ||||||||||
| Interaction | |||||||||||
| Structure map |
| ||||||||||
| Brite | Anatomical Therapeutic Chemical (ATC) classification [BR:br08303] L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS L01 ANTINEOPLASTIC AGENTS L01D CYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCES L01DB Anthracyclines and related substances L01DB06 Idarubicin D01747 Idarubicin hydrochloride (JP18/USP) <JP/US> Therapeutic category of drugs in Japan [BR:br08301] 4 Agents affecting cellular function 42 Antineoplastics 423 Antibiotics 4235 Anthracycline antibiotics D01747 Idarubicin hydrochloride (JP18/USP) Drug groups [BR:br08330] Antineoplastic DG01682 Anthracycline antineoplastic DG00700 Idarubicin D01747 Idarubicin hydrochloride DG01529 Topoisomerase inhibitor DG01527 Topoisomerase II inhibitor DG00700 Idarubicin D01747 Idarubicin hydrochloride Target-based classification of drugs [BR:br08310] Enzymes Isomerases (EC5) DNA topoisomerase TOP2 D01747 Idarubicin hydrochloride (JP18/USP) <JP/US> Drugs listed in the Japanese Pharmacopoeia [BR:br08311] Chemicals D01747 Idarubicin hydrochloride D01747 Idarubicin hydrochloride for injection Drug groups [BR:br08330] Antineoplastic DG01682 Anthracycline antineoplastic DG00700 Idarubicin DG01529 Topoisomerase inhibitor DG01527 Topoisomerase II inhibitor DG00700 Idarubicin | ||||||||||
| Other DBs |
| ||||||||||
| KCF data | ATOM 37 1 X Cl 38.2200 -13.1600 2 C8x C 22.4700 -11.7600 3 C8x C 22.4700 -13.1600 4 C8x C 23.6600 -13.8600 5 C8y C 24.9200 -13.1600 6 C8y C 24.9200 -11.7600 7 C8x C 23.6600 -11.0600 8 C5x C 26.1100 -13.8600 9 C8y C 27.3000 -13.1600 10 C8y C 27.3000 -11.7600 11 C5x C 26.1100 -11.0600 12 C8y C 28.5600 -13.8600 13 C8y C 29.7500 -13.1600 14 C8y C 29.7500 -11.7600 15 C8y C 28.5600 -11.0600 16 C1y C 30.9400 -13.8600 17 C1x C 32.2000 -13.1600 18 C1z C 32.2000 -11.7600 19 C1x C 30.9400 -11.0600 20 O5x O 26.1100 -9.6600 21 O5x O 26.1100 -15.2600 22 O1a O 28.5600 -9.6600 23 O1a O 28.5600 -15.2600 24 C5a C 33.3900 -10.8500 25 C1a C 34.5800 -11.5500 26 O5a O 33.3900 -9.4500 27 O1a O 33.3900 -12.6000 28 O2a O 30.9400 -15.2600 29 C1y C 32.1300 -15.9600 30 C1x C 32.1300 -17.3600 31 C1y C 33.3900 -18.0600 32 C1y C 34.5800 -17.3600 33 C1y C 34.5800 -15.9600 34 O2x O 33.3900 -15.2600 35 C1a C 35.7700 -15.2600 36 O1a O 35.7700 -18.0600 37 N1a N 33.3900 -19.4600 BOND 40 1 2 3 2 2 3 4 1 3 4 5 2 4 5 6 1 5 6 7 2 6 2 7 1 7 5 8 1 8 8 9 1 9 9 10 1 10 10 11 1 11 6 11 1 12 9 12 2 13 12 13 1 14 13 14 2 15 14 15 1 16 10 15 2 17 13 16 1 18 16 17 1 19 17 18 1 20 18 19 1 21 14 19 1 22 11 20 2 23 8 21 2 24 15 22 1 25 12 23 1 26 18 24 1 #Up 27 24 25 1 28 24 26 2 29 18 27 1 #Down 30 16 28 1 #Down 31 29 28 1 #Down 32 29 30 1 33 30 31 1 34 31 32 1 35 32 33 1 36 33 34 1 37 29 34 1 38 33 35 1 #Up 39 32 36 1 #Up 40 31 37 1 #Up |